Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $154.5052W HIGH $284.50
Volume
67.42 K
Value Traded
280.78 M
Short % Float
1.83%
Days to Cover
2.4
-2.29%Week
+0.47%1 Month
+14.56%3 Month
+66.11%6 Month
-29.26%5 Year
+283.68%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
43.64 B
EPS (TTM)
8.47
P/E Ratio
31.57
Ent. Value
57.65 B
Total Shares
164.55 M
Float Shares
163.15 M
Insiders
1.00%
Institutions
101.87%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
IQV Catalyst Timeline
Dated clinical, regulatory and corporate events for IQVIA Holdings, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for IQVIA Holdings, Inc.
114Total events
3Upcoming
10Tier-1 (high impact)
2013 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
IQVIA and Medera announce strategic collaboration to accelerate cardiac gene therapies and human-based drug discovery
●Timing GuidancePresentation
Conference call to discuss Q2 2026 results and Q3/full-year 2026 guidance
◆Debt Royalty FinancingCorporate
IQVIA Inc. intends to raise €950M through offering of senior notes due 2033
▲Partnership / LicenseCorporate
IQVIA and Kexing Biopharm expand strategic collaboration for biosimilar development using AI
◆Oral PresentationPresentation
IQVIA CFO presentation at Bank of America Health Care Conference 2026
◆AcquisitionCorporate
Expected close of acquisition of Charles River Laboratories discovery assets
◆Oral PresentationPresentation
IQVIA CFO to speak at Barclays 28th Annual Global Healthcare Conference
◆Oral PresentationPresentation
CEO Ari Bousbib speaks at Leerink Partners 2026 Global Healthcare Conference
◆Management ChangeCorporate
Michael Fedock appointed CFO effective February 28, 2026; Ron Bruehlman to become Senior Advisor to CEO
◆AcquisitionCorporate
IQVIA signs agreement to acquire drug discovery assets from Charles River Laboratories
▲Partnership / LicenseCorporate
IQVIA and Duke Clinical Research Institute announce strategic collaboration to advance clinical research in obesity and related conditions
obesity and related cardiometabolic conditionssource ↗
●Quarterly UpdateCorporate
IQVIA announces segment reporting changes effective January 1, 2026
▲Runway Guidance UpdateCorporate
IQVIA raises full-year 2026 revenue, Adjusted EBITDA and Adjusted Diluted EPS guidance
▲Equity OfferingCorporate
IQVIA repurchased $212M of common stock in Q4 2025, $1,244M for full year 2025
▲Partnership / LicenseCorporate
IQVIA announces strategic collaboration with AWS, naming AWS as Preferred Agentic Cloud Provider
●Quarterly UpdateCorporate
IQVIA reports Q3 2023 revenue of $3,736 million, GAAP net income $303 million
◆Management ChangeCorporate
Richard Staub III appointed President of Research & Development Solutions
●Quarterly UpdateCorporate
Full-year 2022 revenue guidance updated for FX and Ukraine/Russia crisis
◆Management ChangeCorporate
Costa Panagos appointed President of Research Development Solutions
▲Quarterly UpdateCorporate
IQVIA raises FY 2022 Adjusted EBITDA and Adjusted Diluted EPS guidance
▲Equity OfferingCorporate
IQVIA board approves $2.0B increase in share repurchase authorization
◆AcquisitionCorporate
IQVIA acquires remaining 40% interest in Q2 Solutions from Quest Diagnostics for $760 million
▲Quarterly UpdateCorporate
IQVIA raises full-year 2021 Adjusted Diluted EPS guidance to $7.89-$8.20
Past FDA Catalysts and PDUFA Decisions
How IQV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 61%
Mid Cap(rank 412 of 674)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every IQV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Berkshire James G.Officer (See Remarks) | Option | 5,381 13,558 held | $131.82 | 09/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IQV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 2.1 % (40 %) | 20.44 M | 105.81 K | 22.04% ( 19.11 K) |
Ownership Trends
IQV Short Interest
Shares sold short, counted twice a month.
1.83%
Short % of Float
of tradable shares sold short
3.0M
Shares Sold Short
-7.0% vs prior count
2.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
1.3M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IQV ranks across every disease it competes in
Competitive Position is a premium feature
See how IQV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIQV News
IQVIQVIA Reports Third-Quarter 2026 Results
IQVIA reported third-quarter 2026 results with revenue of $4,428 million, an 8.0% increase year-over-year. Adjusted EBITDA was $1,032 million, up 8.7%, and net new bookings reached $3.2 billion, reflecting a 15% growth. The company raised its full-year guidance for revenue and earnings per share, indicating strong market demand.
Read more →IQVIQVIA Selects Veeva Clinical Operations Applications
IQVIA has expanded its partnership with Veeva Systems by selecting Veeva's CTMS, eTMF, Study Startup, and Site Connect as standard applications for clinical development. This collaboration aims to enhance trial speed and efficiency while providing flexibility for clients to choose their preferred technologies. The announcement was made in conjunction with the upcoming Veeva R&D and Quality Summit.
Read more →IQVIQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes
IQVIA has launched the IQVIA Life Science Models at TechIQ 2026, designed to assist life sciences companies in predicting clinical trial outcomes. This suite of models integrates proprietary content and extensive regulatory knowledge, aiming to improve decision-making in clinical research. The initiative reflects IQVIA's commitment to advancing healthcare intelligence.
Read more →IQVIQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions
IQVIA has launched IQVIA Explorer at TechIQ 2026, aimed at assisting life sciences companies in making informed commercial decisions. This new tool enables users to convert complex analytics projects into a continuous commercial intelligence resource. It allows for the application of external indicators to address business questions effectively.
Read more →IQVIQVIA to Announce Third-Quarter 2026 Results on October 27, 2026
IQVIA Holdings Inc. will announce its third-quarter 2026 financial results on October 27, 2026, before market opening. The management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on the same day. This event highlights the company's commitment to transparency with stakeholders.
Read more →IQVIQVIA Announces Pricing of Senior Notes
IQVIA Holdings Inc. has successfully priced $2 billion in senior notes due 2034. The proceeds will be utilized to redeem existing senior notes due 2026, reduce outstanding debt under its revolving credit facility, and cover associated fees. This move is expected to improve the company's financial position.
Read more →IQVIQVIA Announces Offering of Senior Notes
IQVIA Holdings Inc. has announced a $2 billion senior notes offering due in 2034. The funds will be utilized to fully redeem existing Senior 5.000% Notes due 2026, reduce outstanding debt under its revolving credit facility, and cover related fees and expenses. This move reflects IQVIA's strategic financial management.
Read more →IQVIQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
IQVIA has launched its Predictive Clinical Development, an AI-driven strategy aimed at improving the efficiency of clinical trials. This innovative approach is designed to help life sciences sponsors minimize delays and expedite the introduction of new therapies to patients, potentially reducing the time to market by up to two years. The initiative responds to the growing complexity of clinical trials.
Read more →IQVIQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
IQVIA has been recognized with multiple awards for its innovative use of AI in the life sciences and healthcare sectors. The company aims to enhance decision-making, ensure compliance with regulated workflows, and protect patient privacy. This acknowledgment highlights IQVIA's commitment to optimizing clinical trial execution through advanced technology.
Read more →IQVIQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
IQVIA has announced that its AI-enabled Clinical Decision Support Tool, created in partnership with Breakthrough T1D, has received the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year. This recognition underscores the tool's effectiveness in addressing significant challenges in clinical decision-making through advanced predictive modeling capabilities.
Read more →IQVIQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
IQVIA has been recognized as the top pharmaceutical technology provider by Everest Group for 2026, achieving a remarkable score of 96.8 out of 100. This ranking highlights IQVIA's extensive technology offerings and leadership in the clinical research and healthcare intelligence sectors. The accolade underscores the company's commitment to innovation and excellence in the life sciences industry.
Read more →IQVIQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
IQVIA and Medera have announced a strategic partnership to enhance the development of cardiac gene therapies and human-based drug discovery. This collaboration will utilize IQVIA's clinical trial infrastructure alongside Medera's innovative platforms, Sardocor and Novoheart. The goal is to expedite the delivery of safer and more effective therapies to patients, leveraging advanced regulatory support and human-based alternatives to animal testing.
Read more →IQV▲ +13.9%on this news
IQVIA Reports Second-Quarter 2026 Results
IQVIA Holdings Inc. has announced its financial results for the second quarter of 2026, showcasing a positive performance compared to the previous year. The company has also implemented a new organizational model aimed at improving collaboration and efficiency. This strategic move is expected to further strengthen its position in the clinical research and healthcare intelligence sectors.
Read more →IQVIQVIA's Dr. Cynthia Verst Testifies Before Congressional Subcommittee on More Efficient Path to Early Clinical Development in the United States
Dr. Cynthia Verst from IQVIA testified before the U.S. House Committee on Energy and Commerce, emphasizing the need for reforms to enhance early clinical development in the United States. Her recommendations aim to position the U.S. as a leader in biomedical innovation. The hearing focused on the FDA's role in advancing these initiatives.
Read more →IQVIQVIA to Announce Second-Quarter 2026 Results on July 28, 2026
IQVIA Holdings Inc. will announce its second-quarter 2026 financial results on July 28, 2026, before market opening. The management team will conduct a conference call and webcast at 9:00 a.m. Eastern Time on the same day, providing insights into the company's performance.
Read more →IQVStackAdapt Teams Up with IQVIA Digital’s MediaOS to Power Healthcare Advertising
StackAdapt has partnered with IQVIA Digital's MediaOS to enhance healthcare advertising efforts. This collaboration emphasizes the importance of privacy in advertising, aiming to provide more effective solutions for healthcare marketers. The integration of these technologies is expected to drive innovation in the sector.
Read more →IQVWiley and IQVIA Release Cross-Sector Report on AI’s Promise and Pressure Points Across Healthcare Value Chain
Wiley and IQVIA have collaborated to release a report focusing on the implications of artificial intelligence across the healthcare value chain. The report highlights both the potential benefits and challenges associated with AI integration in healthcare. Further details about the findings and recommendations are expected to be elaborated upon in subsequent communications.
Read more →IQVIQVIA Announces Offering of Senior Notes - June 3, 2026
IQVIA Holdings Inc. announced its intention to raise €950 million through a senior notes offering due in 2033. The proceeds will be utilized to refinance existing debt and cover related fees. The offering is contingent upon market conditions and other customary factors, highlighting potential risks involved.
Read more →About IQVIA Holdings, Inc.
Headquarters2400 ELLIS ROAD, DURHAM, NC, 27703
BIOPHARMAWATCH ELITE PLUS
Trade the next IQV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime